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Abstract The prognosis of pancreatic carcinoma is poor due
to the difficulty in early diagnosis, insensitivity to routine
therapies and limited understanding of its pathological
mechanisms. Gene therapy is now becoming an important
strategy for the treatment of pancreatic carcinoma, which
includes antisense gene therapy. In this study, we investigat-
ed the effect of an antisense oligonucleotide specific to point
mutated K-ras on the apoptosis of human pancreatic carci-
noma cells in vitro. Human pancreatic carcinoma PC-2 cells
were transfected with an antisense oligonucleotide specific
to a K-ras point mutation by liposomes. The effect of the
antisense oligonucleotide on the apoptosis of PC-2 cells
was studied using flow cytometry, TUNEL, and phase
contrast microscopy. An apoptotic peak was observed in
the experimental group, and most cells were arrested at
the G1 phase with few cells at the S phase. The numbers of
apoptotic cells in the experimental group increased as indicat-
ed by TUNEL and phase contrast microscopy. An antisense
oligonucleotide specific to a K-ras point mutation promotes
apoptosis in PC-2 cells in vitro perhaps by inhibition of ras
gene expression.
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Introduction
Pancreatic carcinoma is a digestive malignant tumor that is
difficult to diagnose early and has a poor prognosis. Its
incidence has increased in recent years without significant
progress in therapeutic treatment. The general 5 year survival
rate is as low as 5–10 %, and the improved 5 year survival
rate is about 20–40 % after successive whipple operation
[1]. Early diagnosis is critical for successful surgical
treatment [2].
Significant progress has been made recently in genetic
diagnosis and the treatment of pancreatic carcinoma using
new biological techniques [3–5]. Antisense gene therapy is
now an important strategy of gene therapy [6, 7]. The AUG
start site or 5′ cat site are usually selected as target gene
sequences for the treatment of pancreatic carcinoma [7–9],
but few reports have selected the mute gene as a target. This
study investigated the effect of an antisense oligonucleotide
specific to point mutated K-ras on the apoptosis of human
pancreatic carcinoma cells in vitro.
Methods
The human pancreatic carcinoma cell line PC-2 was cultured
in RPMI 1640 medium supplemented with 10 % fetal bovine
serum in a humidified atmosphere with 5 % CO2. Cells were
divided into two groups with 16 wells of cells each. For the
experimental group, PC-2 cells were transfected with an
antisense oligonucleotide (5′ CTA CGC CAC GAG CTC
CA 3′) specific to a K-ras point mutation and then incubated
for 24 h. For the control group, PC-2 cells were transfected
with a sense oligonucleotide (5′TGG AGC TCG TGG CGT
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AG 3′) and then incubated for 24 h. Oligonucleotides were
transfected by lipofectamine, and cells were cultured for 24 h
followed by total medium exchange after 8 h.
Flow Cytometric Analysis
Cells in logarithmic growthwere digested, washed, resuspended
as single cells and then cultured in a 100 ml culture bottle.
Culture medium was exchanged every 48 h, and oligonucleo-
tides were transfected by lipofectamine at 60 % confluence.
Culture medium was completely exchanged after 8 h of culture.
Cells were then digested, washed, resuspended as single
cells and fixed with 75 % alcohol for 2 h at 4 °C. The
cell cycle, apoptotic peak and percentage were detected
by flow cytometry after staining.
TUNEL Detection
Cells in logarithmic growthwere digested, washed, resuspended
and then cultured in 24-well culture plates with 600 μl
medium/well at 3×105 cells/ml. After 24 h, oligonucleotides
were transfected by lipofectamine. Culture medium was
completely exchanged after 8 h of culture. Cells were then
stained and photographed after 48 h according to the TUNEL
protocol.
Phase Contrast Microscopy
Cells in logarithmic growth were harvested and cultured in a
100 ml culture bottle. Culture medium was exchanged every
48 h, and oligonucleotides were transfected by lipofectamine
at 60 % confluence. Culture medium was completely ex-
changed after 8 h of culture. After 48 h, apoptotic bodies were
detected and photographed under an inverted phase contrast
microscope. According to the number of labeled cells, labeled
was designated as – (0), + (1–5), ++ (6–10), and +++ (>10).
The number of apoptotic cells was analyzed by SPSS 10.0
statistical software.
Results
Flow Cytometer Results
There was an apparent apoptotic peak before the G1 phase of
the cell cycle in the experimental group. The apoptotic rate
was 31.8 % in the experimental group. There was no appar-
ent apoptotic peak in the control group (Figs. 1 and 2). Most
cells in the experimental group were arrested at the G1 phase,
and the number of S phase cells was decreased compared
with that of the control group (P=0.038) (Table 1),
indicating an increase in apoptotic cells and a decrease
of cell proliferation after transfection with the antisense
oligonucleotide.
TUNEL Results
The characteristics of apoptotic cells were observed under a
microscope after TUNEL, in which labeled cells showed
brown yellow granules in the nucleus. Five fields of vision
were selected randomly for each group under×400 magnifi-
cation, and labeled cells were counted and averaged. The
number of apoptotic cells in the experimental group in-
creased compared with that of the control group (P=0.026)
(Table 2, Fig. 3 and 4).
Fig. 1 Cell cycle distribution histogram of the control group
(There was no apparent apoptotic peak before G1 phase in the
cell cycle)
Fig. 2 Cell cycle distribution histogram of the experimental group
(There was an apparent apoptotic peak before G1 phase in the cell
cycle)
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Phase Contrast Microscopy Results
Apoptotic bodies were observed under an inverted phase
contrast microscope after 48 h of culture. The number of
cells with apoptotic bodies in the experimental group in-
creased compared with that of the control group. The shape
of apoptotic cells became atrophic and rounded, and some
little froth or ball-shaped apoptotic bodies were observed on
the apoptotic cell surface. Some cells detached from the
culture vessel and were suspended in the medium (Figs. 5
and 6).
Discussion
Excessive cell proliferation and abnormal differentiation are
major reasons of tumor occurrence, and deregulation of cell
death is a major factor for the occurrence of carcinoma. Cell
proliferation and cell death are accurately balanced under a
normal condition, and carcinoma occurs once this balance is
disrupted.
Cell death is generally classified into two types, necrosis
and apoptosis. Cell apoptosis is a form of programmed cell
death and occurs when cells receive certain signals or stim-
ulation. Moreover, cell apoptosis is a method of clearing
injured or nonfunctioning cells from the body without
changing the function of the tissue. Cell apoptosis plays an
important regulatory role under normal and pathological
conditions.
Previous studies have mainly focused on the excessive
proliferation of carcinoma cells as the mechanism of carci-
noma occurrence. It has been recently found that cell apo-
ptosis participates in the occurrence of carcinoma at several
phases. Excessive cell proliferation may trigger excessive
cell cloning whereas apoptosis can restrain it.
It has been reported that cell apoptosis is blocked in the
early stage of carcinoma occurrence [10], indicating that it
may be possible to treat carcinoma by inducing cell apopto-
sis. Under normal condition, cell apoptosis can clear DNA-
injured and potentially malignant cells. Disruption of apo-
ptotic function can promote the development of carcinoma
[11]. Inducing apoptosis may reduce DNA-injured and po-
tentially malignant cells and thus prevent or inhibit carcino-
ma growth. In contrast, inhibition of apoptosis may facilitate
pre-carcinoma cells. Arya et al. reported that stimulating cell
apoptosis can be an anti-carcinoma strategy [12]. Inducing
apoptosis in carcinoma cells appears to be more physiolog-
ical than killing carcinoma cells directly because it avoids the
side effects of chemotherapeutic drugs. The dynamic balance
between cell proliferation and cell apoptosis has a major
effect on the initiation of pre-carcinoma and carcinoma cells,
and cell apoptosis has an important function in the non-
transmissibility of carcinogenic course.
Table 1 Cell cycle distribution
Cell cycle distributing
G1 S G2
Experimental group 59.8 % 29.0 % 11.2 %
Control group 50.2 % 49.7 % 0.1 %
P value P=0.29 P=0.038 P=0.029
Table 2 Comparison of cell apoptosis between the two groups
Apoptosis cells Expression rate P value
- + ++ +++
Experimental group 2 3 4 1 80 % P=0.026
Control group 8 2 0 0 20 %
Fig. 3 Apoptotic cells in the control group (TUNEL, ×400)
Fig. 4 Apoptotic cells in the experimental group (TUNEL, ×400)
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Cell apoptosis is regulated by two mechanisms, namely
programmed gene regulation such as the replacement of old
cells with new cells under a physiological condition, and
non-gene regulation in which injury factors, such as TGF-β
and TNF, damage DNA directly or indirectly and thereby
disturb cell proliferation and induce cell apoptosis.
Most studies of cell apoptosis have focused on the effect
of apoptotic genes on apoptosis. Few studies have focused
on the effect of the cancer gene on cell apoptosis. It has been
reported that cell apoptosis is related to the expression level
of the cancer gene. A potential approach to restrict the ex-
pression of the cancer gene may be via inducing cell apoptosis
[13]. Many reports have shown that the ras gene can increase
cell proliferation [14, 15], but few studies show the effect of
the ras gene on cell apoptosis. We have previously reported an
antisense oligonucleotide specific to a K-ras point mutation,
which can inhibit the expression of the ras gene [16]. Our
study showed that the experimental group had significantly
increased apoptosis.
It has been reported that the ras protein not only regulates
cell proliferation and differentiation, but also promotes car-
cinoma occurrence by inhibiting cell apoptosis17. Kinoshita
et al. reported that apoptosis of hematogenous cells is
inhibited after transfection of the of k-ras gene in vitro.
Further study showed that this effect is caused by an increase
in bcl-2 gene expression [15]. Ward et al. reported that the
decrease in cell apoptosis is closely related to activation of
the k-ras gene [17, 18]. The first mechanism may be early
genetic changes that desensitize cells to apoptotic stimuli, and
then silenced gene expression is easily transferred to the next
generation [19]. The second mechanism may involve activa-
tion of the ras protein, which may inhibit apoptosis directly or
indirectly. Mizukami et al. reported that farnesylamine can
inhibit the ras protein on the membrane and the ras signaling
pathway to promote cell apoptosis [20]. It has been shown that
the ras protein plays an important role in the regulation of cell
apoptosis.
The ras gene plays an important role in the multiple
steps of carcinoma development. The ras gene regulates
the expression of many other genes that have important
functions in regulating the mutual effect between carci-
noma and the host. Fenton et al. reported that the fas
mRNA level in cells transfected with the ras gene de-
creases significantly, indicating that the ras gene can
restrict the expression of fas via several mechanisms
[21]. Fushida et al. reported that human pancreatic car-
cinoma cells transfected with the ras gene lose fas
receptor function at various levels of the fas signal
transduction pathway [22]. Gulbins et al. reported that
apoptosis induced by the fas gene is mediated by the
ras signaling pathway, and activation of the ras gene is
the key step in this apoptotic pathway because apoptosis
induced by the fas gene can be inhibited by an antibody that
inhibits or counteracts ras gene mutation [23]. Moreover,
blocking the fas gene can stimulate the sphingomyelin signal-
ing pathway to produce acyl sphingosine that can acti-
vate the ras gene and induce apoptosis. It has been
shown that ras and fas genes are inter-regulated to
induce cell apoptosis. However, the ras gene can pro-
mote tumor occurrence by inhibiting tumor cell apopto-
sis by several mechanisms.
Our study indicates that an antisense oligonucleotide
specific to a K-ras point mutation can promote apopto-
sis of the human pancreatic carcinoma cell line PC-2
in vitro, which is likely mediated by inhibition of ras
gene expression.
Fig. 5 Apoptotic bodies in the experimental group (Phase contrast
microscopy, ×100)
Fig. 6 Apoptotic bodies in the control group (phase contrast micros-
copy, ×100)
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